D-cycloserine: An evolving role in learning and neuroplasticity in schizophrenia

Schizophrenia Bulletin

Volumn 38, Issue 5, 2012, Pages 936-941

  Goff, Donald C ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cognitive behavioral; D cycloserine; memory consolidation; negative symptoms; NMDA; therapy

Indexed keywords

CLOZAPINE; CYCLOSERINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PHENCYCLIDINE; PLACEBO;

ANIMAL BEHAVIOR; ARTICLE; COGNITION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; HUMAN; LEARNING; LOW DRUG DOSE; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; TREATMENT OUTCOME;

AFFECT; ANIMALS; AROUSAL; BRAIN; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; CYCLOSERINE; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEARNING; MAGNETIC RESONANCE IMAGING; MEMORY; MEMORY, SHORT-TERM; MOTIVATION; NEURONAL PLASTICITY; QUALITY OF LIFE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84866703056     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbs012     Document Type: Article

References (50)

1. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Research. 1990;510:158-160.
2. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995;152:1213-1215.
3. Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999;56(1):21-27.
4. Cascella NG, Macciardi F, Cavallini C, Smeraldi E. d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm [Gen Sect]. 1994;95:105-111.
5. Simeon J, Fink M, Itil T, Ponce D. d-Cycloserine therapy of psychosis by symptom provocation. Comp Psychiatry. 1970;11:80-88.
6. Yurgelun-Todd DA, Coyle JT, Gruber SA, Renshaw PF, Silveri MM, Amico E, Cohen B, Goff DC. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005;138(1):23-31.
7. Yamada S, Harano M, Annoh N, Nakamura K, Tanaka M. Involvement of serotonin 2A receptors in phencyclidineinduced disruption of prepulse inhibition of the acoustic startle in rats. Biol Psychiatry. 1999;46:832-838.
8. Corbett R, Camacho R, Woods AT, et al. Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology. 1995;120: 67-74.
9. Malhotra A, Adler C, Kennison S, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry. 1997;42: 664-668.
10. Goff DC, Tsai G,Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153:1628-1630.
11. Goff D, Henderson D, Evins A, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;45:512-514.
12. Goff DC, Hennen J, Tsai G, Evins AE, Yurgelun-Todd D, Renshaw P. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry. 2002;51:493-497.
13. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002;159:480-482.
14. Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J. Double-blind, placebo-controlled, crossover trial of Dcycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 1998;3:131-135.
15. van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RS. Efficacy and tolerance of Dcycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996;40:1298-1300.
16. van Berckel BNM, Evenblij CN, van Loon BJAM, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21:203-210.
17. Goff DC, Herz L, Posever T, et al. A six-month, placebocontrolled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005;179(1):144-150.
18. Duncan EJ, Szilagyi S, Schwartz MP, et al. Effects of Dcycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004;71:239-248.
19. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164: 1593-1602.
20. Davis M, Ressler K, Rothbaum BO, Richardson R. Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60:369-375.
21. Dravid SM, Burger PB, Prakash A, et al. Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors. J Neurosci. 2010;30:2741-2754.
22. Sheinin A, Shavit S, Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology. 2001;41(2):151-158.
23. Emmett M, Mick S, Cler J. Actions of D-cycloserine at the Nmethyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacol. 1991;30:1167-1171.
24. Karavanova I, Vasudevan K, Cheng J, Buonanno A. Novel regional and developmental NMDA receptor expression patterns uncovered in NR2C subunit-beta-galactosidase knock-in mice. Mol Cell Neurosci. 2007;34:468-480.
25. Beneyto M, Meador-Woodruff JH. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder. Neuropsychopharmacology. 2008;33:2175-2186.
26. Zhang Y, Llinas RR, Lisman JE. Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting. Front Neural Circuits. 2009;3:20.
27. Hillman BG, Gupta SC, Stairs DJ, Buonanno A, Dravid SM. Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiol Learn Mem. 2011;95:404-414.
28. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention. Eur J Pharm. 1994;257:7-12.
29. Matsuoka N, Aigner TG. D-cycloserine, a partial agonist at the glycine site coupled to N-methyl-D-aspartate receptors, improves visual recognition memory in rhesus monkeys. J Pharmacol Exp Ther. 1996;278:891-897.
30. Santini E, Muller RU, Quirk GJ. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci. 2001;21:9009-9017.
31. Langton JM, Richardson R. D-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology. 2008;33:3096-3102.
32. Parnas AS, Weber M, Richardson R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem. 2005;83:224-231.
33. Nong Y, Huang YQ, Ju W, et al. Glycine binding primes NMDA receptor internalization. Nature. 2003;422:302-307.
34. Goff DC,CatherC,Gottlieb JD, et al.Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008;106:320-327.
35. Nadel L, Samsonovich A, Ryan L, Moscovitch M. Multiple trace theory of human memory: computational, neuroimaging, and neuropsychological results. Hippocampus. 2000;10:352-368.
36. Manoach DS, Stickgold R. Does abnormal sleep impair memory consolidation in schizophrenia? Front Hum Neurosci. 2009;3:21.
37. Holt DJ, Lebron-MiladK,MiladMR, et al. Extinction memory is impaired in schizophrenia. Biol Psychiatry. 2009;65:455-463.
38. Manoach DS, Thakkar KN, Stroynowski E, et al. Reduced overnight consolidation of procedural learning in chronic medicated schizophrenia is related to specific sleep stages. J Psychiatr Res. 2010;44(2):112-120.
39. Ferrarelli F, Huber R, Peterson MJ, et al. Reduced sleep spindle activity in schizophrenia patients. Am J Psychiatry. 2007;164:483-492.
40. Burgos-Robles A, Vidal-Gonzalez I, Santini E, Quirk GJ. Consolidation of fear extinction requires NMDA receptordependent bursting in the ventromedial prefrontal cortex. Neuron. 2007;53:871-880.
41. Herbener ES. Impairment in long-term retention of preference conditioning in schizophrenia. Biol Psychiatry. 2009;65: 1086-1090.
42. Gard DE, Kring AM, Gard MG, Horan WP, Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93(1-3): 253-260.
43. Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC. D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schiz Res. 2011;131: 69-74.
44. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523-537.
45. Yaka R, Biegon A, Grigoriadis N, et al. D-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 2007;21:2033-2041.
46. Adeleye A, Shohami E, Nachman D, et al. D-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window. Eur J Pharmacol. 2010; 629(1-3):25-30.
47. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Chen R. Dysfunctional neural plasticity in patients with schizophrenia. Arch Gen Psychiatry. 2008;65:378-385.
48. Butefisch CM, Davis BC, Wise SP, et al. Mechanisms of usedependent plasticity in the human motor cortex. Proc Natl Acad Sci USA. 2000;97:3661-3665.
49. Monaghan DT, Larsen H. NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology. J Pharmacol Exp Ther. 1997;280:614-620.
50. Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W. Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology. 2004;29: 1573-1578.